Filing Details
- Accession Number:
- 0001209191-10-044850
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-09-02 14:38:01
- Reporting Period:
- 2010-09-01
- Filing Date:
- 2010-09-02
- Accepted Time:
- 2010-09-02 14:38:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
901219 | Human Genome Sciences Inc | HGSI | In Vitro & In Vivo Diagnostic Substances (2835) | 223178468 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1332456 | Barry Labinger | 14200 Shady Grove Road Rockville MD 20850 | Exec Vp & Cco | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-09-01 | 50,000 | $4.92 | 50,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2010-09-01 | 50,000 | $30.02 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee stock option right to buy | Disposition | 2010-09-01 | 50,000 | $0.00 | 50,000 | $4.92 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
70,871 | 2018-03-10 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 6/16/10.
- This transaction was executed in multiple trades at prices ranging from $30.00 to $30.06. The price reported above reflects the weighted average sales price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
- One-eighth of the 150,000 options granted on March 10, 2008, vested on the six-month anniversary date (September, 2008) and the remaining options granted vested and continue to vest monthly on a ratable basis for the next 42 months commencing on October 10, 2008.